[123I] β-CIT SPECT imaging assessment of the rate of Parkinson's disease progression

Neurology

Volumn 57, Issue 11, 2001, Pages 2089-2094

  Marek, Kenneth ^a,c   Innis, R ^a   Van Dyck, C ^a   Fussell, B ^a   Early, M ^a   Eberly, S ^b   Oakes, D ^b   Seibyl, J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c INSTITUTE FOR NEURODEGENERATIVE DISORDERS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; DOPAMINE TRANSPORTER; IODINE 123; CARRIER PROTEIN; COCAINE; DIAGNOSTIC AGENT; DOPAMINE BINDING PROTEIN; DOPAMINE-BINDING PROTEIN; DRUG DERIVATIVE;

ADULT; AGED; APPARATUS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; DRUG UPTAKE; FEMALE; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; NERVE CELL DEGENERATION; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PRIORITY JOURNAL; QUANTITATIVE ASSAY; RATING SCALE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; UNITED STATES; CAUDATE NUCLEUS; CORPUS STRIATUM; FOLLOW UP; HEMISPHERIC DOMINANCE; NEUROLOGIC EXAMINATION; PATHOPHYSIOLOGY; PHYSIOLOGY; PUTAMEN; REFERENCE VALUE; SCINTISCANNING;

AGED; CAUDATE NUCLEUS; COCAINE; CORPUS STRIATUM; DISEASE PROGRESSION; DOMINANCE, CEREBRAL; FEMALE; FOLLOW-UP STUDIES; HUMAN; MALE; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGE; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; PUTAMEN; REFERENCE VALUES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0035846468     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.57.11.2089     Document Type: Article

References (43)

1. Parkinsonism. Onset, progression and mortality
2. Parkinson's disease is not a long-latency illness
3. Is idiopathic parkinsonism the consequence of an event or a process?
4. Does a long preclinical period occur in Parkinson's disease
5. The next frontier in Parkinson's disease: Presymptomatic detection
6. Rate of cell death in parkinsonism is an active neuropathological process
7. Ageing and Parkinson's disease: Substantia nigra regional selectivity
8. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease
9. Brain dopamine and the syndromes of Parkinson and Huntington, clinical, morphological, and neurochemical correlates
10. The neuropathological basis of different clinical subgroups of Parkinson's disease
11. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease
12. Unified Parkinson's disease rating scale
13. Immediate-release and controlled-release carbidopa/levodopa in PD: A 5-year randomized multicenter study
14. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa
15. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET
16. Clinical and [18F]dopa PET findings in early Parkinson's disease
17. [123I]FP-SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease
18. Rapid detection of Parkinson's disease by SPECT with Altropane: A selective ligand for dopamine transporters
19. [11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease
20. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease
21. 11C-WIN 35,428 reveals marked decline in mild Parkinson's disease
22. Progression in Parkinson's disease: A positron emission tomography study with a dopamine transporter ligand [18F]CFT
23. 123I] β-CIT binding to dopamine transporters in healthy human subjects
24. Imaging of dopamine transporters with iodine- 123-B-CIT and SPECT in Parkinson's disease
25. 123I] βCIT striatal uptake correlates with symptom severity in idiopathic Parkinson's disease
26. 123] CIT SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease
27. Core assessment program for intracerebral transplantations (CAPIT)
28. 123I] β-CIT) in Nonhuman primates: pharmacokinetics, biodistribution, and SPECT brain imaging coregistered with MRI
29. A method for attenuation correction in computed tomography
30. Novel radioligands for the dopamine transporter demonstrate the presence of intrastriatal nigral grafts in the MPTP-treated monkey: Correlation with improved behavioral function
31. Decreased density of human striatal dopamine uptake sites with age
32. 123I] β-CIT SPECT
33. Decreased dopamine transporters with age in healthy human subjects
34. 123I] β-CIT SPECT brain measurement of dopamine transporters in healthy human subjects
35. 123I] B-CIT SPECT brain measurement of dopamine transporters in Parkinson's disease patients
36. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease
37. Clinical and [18F]dopa PET findings in early Parkinson's disease
38. 123I]B-CIT
39. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease
40. Variable expression of Parkinson's disease: A baseline analysis of the DATATOP cohort
41. Experimental therapeutic of neurodegenerative disorders: Unmet needs
42. Parkinson disease, the effect of levodopa, and the ELLDOPA trial
43. Design of a clinical trial comparing pramipexole to levodopa in early PD (CALM-PD)